{"schema_version":"secwatch.filing_event.v1","accession":"0001944048-24-000136","form_type":"8-K","ticker":"KVUE","cik":"0001944048","company_name":"Kenvue Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.246701+00:00","generated_at":"2026-05-31T12:41:56.630940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kenvue Q2 adjusted EPS $0.32, organic sales +1.5%; reaffirms FY24 outlook","bullets":["Net sales $4.0B, down 0.3% YoY; organic growth +1.5% (value realization +2.1%, volume -0.6%).","Diluted EPS $0.03; adjusted diluted EPS $0.32 vs $0.31 prior year; adjusted operating margin 22.8% vs 23.1%.","Non-cash impairment charge of $488M ($337M after-tax) on Dr.Ci:Labo assets due to China market dynamics.","FY24 outlook reaffirmed: net sales growth 1%-3%, organic growth 2%-4%, adjusted EPS $1.10-$1.20.","Gross profit margin expanded 360 bps to 59.1%; adjusted gross margin expanded 410 bps to 61.6%."],"urls":{"canonical":"https://secwatch.observer/filing/0001944048-24-000136","json":"https://secwatch.observer/filing/0001944048-24-000136.json","markdown":"https://secwatch.observer/filing/0001944048-24-000136.md","text":"https://secwatch.observer/filing/0001944048-24-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1944048/000194404824000136/0001944048-24-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1944048/000194404824000136/kvue-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:41:56.630940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}